Literature DB >> 36254030

Network pharmacology study on the potential effect mechanism of Chuanzhi Tongluo Capsule in the treatment of cerebral infarction.

Shan Ma1, Wenhui Fan, Jianxin Zhang.   

Abstract

BACKGROUND: Chuanxiong Tongluo capsules have been widely used to treat recovered stroke and cerebral infarction, but their specific therapeutic mechanism is not well understood.
METHODS: This study aims to investigate the mechanism of action for Chuanzhi Tongluo capsule on cerebral infarction based on a network pharmacology approach. The TCMSP platform collected the chemical composition of Chuanzhi Tongluo capsules. Its potential targets were predicted by Swiss target prediction and standardized using the Uniprot database for gene normalization. Meanwhile, the OMIM, Genecards, and TTD databases were used to obtain the targets related to cerebral infarction. The standard targets of Chuanzhi Tongluo capsule and cerebral infarction were uploaded to the STRING database to construct protein-protein interaction networks. Topological methods analyzed the key targets and components in the drug-component-disease-target network. Gene ontology function and Kyoto Encyclopedia of Genes and Genomes pathway enrichment analysis of the shared targets were performed using the DAVID database.
RESULTS: A total of 105 active ingredients and 427 targets were associated with Chuanzhi Tongluo capsule, and there were 3055 targets related to cerebral infarction disease and 240 common targets between the two keywords. The key targets included INS, ALB, IL-6, VEGFA, TNF, and TP53. The conduction pathways involved include the calcium signaling pathway, cAMP signaling pathway, cGMP-PKG signaling pathway, and TNF signaling pathway.
CONCLUSION: The active ingredients in Chuanzhi Tongluo capsule may participate in the therapeutic process of cerebral infarction by regulating the calcium, cAMP, cGMP-PKG, and TNF signaling pathway through critical targets such as INS, ALB, IL-6, VEGFA, TNF, and TP53.
Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 36254030      PMCID: PMC9575740          DOI: 10.1097/MD.0000000000030916

Source DB:  PubMed          Journal:  Medicine (Baltimore)        ISSN: 0025-7974            Impact factor:   1.817


  27 in total

Review 1.  Network pharmacology: the next paradigm in drug discovery.

Authors:  Andrew L Hopkins
Journal:  Nat Chem Biol       Date:  2008-11       Impact factor: 15.040

Review 2.  Potential new risk factors for ischemic stroke: what is their potential?

Authors:  Graeme J Hankey
Journal:  Stroke       Date:  2006-06-29       Impact factor: 7.914

3.  Effect of mannitol on cerebral blood volume in patients with head injury.

Authors:  Michael N Diringer; Michael T Scalfani; Allyson R Zazulia; Tom O Videen; Rajat Dhar; William J Powers
Journal:  Neurosurgery       Date:  2012-05       Impact factor: 4.654

4.  Hederagenin and α-hederin promote degradation of proteins in neurodegenerative diseases and improve motor deficits in MPTP-mice.

Authors:  An-Guo Wu; Wu Zeng; Vincent Kam-Wai Wong; Yi-Zhun Zhu; Amy C Y Lo; Liang Liu; Betty Yuen-Kwan Law
Journal:  Pharmacol Res       Date:  2016-11-09       Impact factor: 7.658

5.  Bilateral lesions of the fastigial nucleus prevent the recovery of blood pressure following hypotension induced by hemorrhage or administration of endotoxin.

Authors:  L O Lutherer; B C Lutherer; K J Dormer; H F Janssen; C D Barnes
Journal:  Brain Res       Date:  1983-06-20       Impact factor: 3.252

6.  Unraveling the binding mechanism of asiatic acid with human serum albumin and its biological implications.

Authors:  Mahesh Gokara; Tirupathi Malavath; Suresh Kumar Kalangi; Pallu Reddana; Rajagopal Subramanyam
Journal:  J Biomol Struct Dyn       Date:  2013-07-11

7.  The human Tp53 Arg72Pro polymorphism explains different functional prognosis in stroke.

Authors:  Jose C Gomez-Sanchez; Maria Delgado-Esteban; Irene Rodriguez-Hernandez; Tomas Sobrino; Natalia Perez de la Ossa; Silvia Reverte; Juan P Bolaños; Rogelio Gonzalez-Sarmiento; Jose Castillo; Angeles Almeida
Journal:  J Exp Med       Date:  2011-02-28       Impact factor: 14.307

8.  Inhibition of angiogenesis, fibrosis and thrombosis by tetramethylpyrazine: mechanisms contributing to the SDF-1/CXCR4 axis.

Authors:  Xiaoxiao Cai; Zhao Chen; Xueke Pan; Lei Xia; Pei Chen; Ying Yang; Huan Hu; Jing Zhang; Kaijing Li; Jian Ge; Keming Yu; Jing Zhuang
Journal:  PLoS One       Date:  2014-02-05       Impact factor: 3.240

Review 9.  Studies of selective TNF inhibitors in the treatment of brain injury from stroke and trauma: a review of the evidence to date.

Authors:  Antonino Tuttolomondo; Rosaria Pecoraro; Antonio Pinto
Journal:  Drug Des Devel Ther       Date:  2014-11-07       Impact factor: 4.162

10.  Worse Neurological State During Acute Ischemic Stroke is Associated with a Decrease in Serum Albumin Levels.

Authors:  Joanna Bielewicz; Jacek Kurzepa; Elżbieta Czekajska-Chehab; Piotr Kamieniak; Beata Daniluk; Halina Bartosik-Psujek; Konrad Rejdak
Journal:  J Mol Neurosci       Date:  2016-01-12       Impact factor: 3.444

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.